Peter Buhl Jensen has 35 years of experience in clinical cancer therapy and as a serial entrepreneur. He is the founder/co-founder of Oncology Venture A/S, TopoTarget A/S which he also led as the CEO. He has also co-founded and CHOSA ApS, and Buhl Oncology ApS and has been key in the development and approval of the cancer drugs Savene® (EU approval 2006, FDA 2007) & Belinostat® (FDA approval 2014).  Buhl Jensen was the Chief Oncologist and chief executive at the Oncology department at Rigshospitalet (2000-08), and Aalborg University Hospital (2010-11).

Holdings in the Company:  15,506,935* shares, corresponding to approximately 24.7 percent of the shares in the Company.

Claus Frisenberg Pedersen, born in 1972, has a master’s degree in strategy and organizational development from Copenhagen Business School and a Diploma (HD) in finance from Copenhagen Business School. Frisenberg Pedersen has long experience as a strategic advisor, with a primary focus on M&A, FMCG and Commercial Excellence. Frisenberg Pedersen also has management and founding experience from the biotechnology sector (Oncology Venture ApS; 2X Oncology Ltd.).Claus Frisenberg Pedersen’s other assignments include: Chairman of the Board of 2Ø ApS, Finn L & Davidsen A/S, Servicelovers ApS and SJEB A/S. Board member of Nel-lemann Holding A/S.

After the completion of the acquisition of CHOSA, Claus Frisenberg Pedersen will indirectly hold 7,332,952 shares in the Company.

Ulla Hald Buhl, born 1964, a degree in health care administration from the University of Southern Denmark, a bachelor’s degree in nursing, and has completed the Board Leadership Masterclass at Copenhagen Business School. Hald Buhl has 25 years of experience in the biotech sector as a serial entrepreneur, founder and/or co-founder (Oncology Venture A/S, 2X Oncology Ltd., Cessatech A/S, Buhl Oncology ApS, CHOSA Oncology ApS and Aïda Oncology ApS) and has been involved in several IPOs (WntResearch AB, MPI A/S, Oncology Venture A/S, and Cessatech A/S) as well as two product approvals (Savene® and Belinostat®).Ulla Hald Buhl’s other assignments include: managing director of Aïda Oncology ApS and Buhl Krone Holding ApS.

Ulla will together with Peter hold 15 506 935 shares corresponding to approximately 24.7 percent of the shares in Rhovac after the merger.

Ingrid Atteryd Heiman, born in 1958, has a bachelor’s degree in finance and industrial marketing from Lund University and a MBA in International Business from Uppsala University. Atteryd Heiman has broad experience in business management and board work from food, pharmaceuticals, biomedicine, life science, women’s health and financial services, as well as international business including business development in Europe, the USA and Asia.Atteryd Heiman’s other assignments include: Board member of Amniotics AB (publ), CarpoNovum AB, Ilama AB, Pharmiva AB (publ), Redwood Pharma AB (publ) and VitalSigns AB.

Ingrid Atteryd Heiman does not hold any shares in the Company.

Gerton Jönsson (born 1971) has worked for around 20 years as an accounting consultant for both large international groups and for smaller companies, both listed and unlisted. Been acting CFO for different companies such as Doxa AB and Amniotics AB and is now also acting CFO for Zaplox AB and Aqua Nobel of Sweden AB. He has broad experience of the various elements required of a CFO at a smaller listed company.

Education: ADB-linjen Mälardalens högskola 1992 Holdings in the company: 0 Shares

Neil Goldsmith, born in 1963, is a British citizen and resident in Denmark, and has a first-class honors degree in zoology from the University of Oxford. He has a 35-year track record of building life science companies. Over the years, he has been a co-founder of several listed companies (Evolva SA; Personal Chemistry AB and Topotarget A/S) and had executive roles in additional companies. Goldsmith’s other assignments include: Board Member of Conarium Biosystems LLC, Double Bioventures Ltd, Merian Life Sciences ApS, Sundew ApS and Unibio plc. Partner in 1632 LLP.

After the completion of the acquisition of CHOSA, Neil Goldsmith will indirectly hold 2,371,606 shares in the Company.

Morten Myrhøj, born in 1967, has a master degree in business law from Aalborg University. Morten has more than 15 years’ experience as senior M&A advisor with primary focus on small-and midcap listet companies. Recently Morten has more than 10 years’ experience as owner and ceo of a Danish real estate company which has recently been divested to a Danish institutional investor. Mortens other assignments include: Chairman of the board in Drosbjerg Viby J. A/S, Grønningen Strib A/S, H. N. Clausens Gade Aarhus A/S, Markedsgade Hjørring A/S, PlusEjendomme A/S and Rosenvænget Skødstrup A/S. Board member in PlusEjendomme Invest ApS, SC Administration A/S and Skøjtehaven Holding A/S. Chief Executive Officer in Skøjtehaven Holding A/S. Member of the management team in BC Gold ApS, Komplementaranpartsselskabet Sporparken, Myrhøj & Dahl ApS, Myrhøj 1 ApS, MYRHØJ ApS, MYRHØJ HOLDING ApS, MYRHØJ INVEST ApS, Skøjtehaven ApS, Skøjtehaven Byg ApS, Skøjtehaven Randers ApS, Sporparken, Randers P/S and Toffee ApS.

Fred R. Hirsch, MD, PhD, is Executive Director at the Center for Thoracic Oncology and Co-Director of the Center of Excellence for Thoracic Oncology at The Tisch Cancer Institute at Mount Sinai, New York, and the Joe Lowe and Louis Price Professor of Medicine (Hematology and Medical Oncology) at the Icahn School of Medicine at Mount Sinai. He is also Associate Director of Biomarker Discovery for TCI.

Before joining Mount Sinai, Dr. Hirsch was a Professor of Medicine and Pathology at the University of Colorado for 18 years and Chief Executive Officer of the International Association for the Study of Lung Cancer (IASLC) for five years. Dr. Hirsch has received a number of awards and honors, including the IASLC Mary Matthews Award for Translational Research in Lung Cancer in 2007; the Japanese Lung Cancer Society Merit Award in 2010; the Addario Foundation Lecture Award in 2015; and the Wuan Ki Hong Lectureship Award in 2019.

Dr. Hirsch has also contributed to more than 400 publications in peer-reviewed journals. He is an internationally renowned authority on lung cancer treatment and research.

Dr. Hirsch does not hold any shares in CHOSA Oncology, and is considered to be independent both in relation to the company and its management and in relation to its major shareholders.